Q-omics provides the consensus-scored MIR2276 profile across patient tissues and cancer cell-line models. MIR2276 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, MIR2276 is differentially expressed in 3, with the highest sampling consensus in STAD. Additionally, MIR2276 RNA expression shows 6,249 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight READ, STAD, and ESCA as cancer lineages where MIR2276 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR2276 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR2276 survival associations across molecular data types. MIR2276 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR2276 RNA expression–survival associations across cancer types. High MIR2276 expression shows unfavorable associations in READ, UCEC, UVM, THYM and KIRP, but favorable associations in KIRC. The READ Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify READ as the clearest survival context for MIR2276 RNA expression.
This table summarizes MIR2276 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for MIR2276. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR2276 shows lower tumor expression in LUSC and KIRC and higher tumor expression in STAD. The STAD box plot shows higher MIR2276 RNA expression in tumor versus normal tissue (log2 FC = +0.393, t-test p = .001).
This table shows molecular features associated with MIR2276 in patient tissues and cancer cell lines. In patient samples, MIR2276 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
